Table 2 |
||||||||||
|
Effects of zafirlukast in asthmatic subjects maintained on β2-agonists alone |
||||||||||
| β2-agonists alone + Placebo Change from baseline |
β2-agonists alone + Zafirlukast Change from baseline |
|||||||||
|
|
||||||||||
| Baseline (N = 7) |
Weeks 0–5 (N = 6) |
Weeks 6–10 (N = 5) |
Week 11–12 (N = 5) |
*W/D (N = 5) |
Baseline (N = 14) |
Weeks 0–5 (N = 13) |
Weeks 6–10 (N = 12) |
Week 11–12 (N = 12) |
*W/D (N = 11) |
|
|
|
||||||||||
| Daily PEFR a.m., L/min |
375 (± 36.7) |
-17.3 (± 8.6) |
-12.2 (± 10.3) |
+0.8 (± 7.5) |
-1.2 (± 4.3) |
408 (± 30.9) |
+14.9 (± 7.9) |
+1.6 (± 8.5) |
-3.2 (± 11.5) |
-30.7 (± 10.9) |
| Daily PEFR p.m., L/min |
374 (± 35.0) |
+4.9 (± 6.6) |
+14.2 (± 10.7) |
+21.2 (± 11.7) |
-9.4 (± 8.9) |
430 (± 27.4) |
+4.2 (± 4.4) |
-0.08 (± 5.7) |
-5.8 (± 7.5) |
-12.7 (± 8.2) |
| FEV1, mL |
2.82 (± 0.33) |
-170 (± 80) |
+20.0 (± 10) |
-258 (± 213) |
+7.2 (± 128) |
2.90 (± 0.16) |
+110 (± 60) |
-12.5 (± 6.9) |
+14.2 (± 72) |
-214 (± 69.8) |
| β2-agonist use per day |
4.6 (± 0.9) |
-0.7 (± 0.3) |
-1.3 (± 0.4) |
-0.6 (± 0.5) |
+0.2 (± 0.5) |
3.7 (± 0.5) |
-0.7 (± 0.4) |
-0.4 (± 0.5) |
+0.2 (± 0.5) |
+0.6 (± 0.3) |
| Severity score |
1.9 (± 0.05) |
-0.2 (± 0.1) |
-0.3 (± 0.1) |
-0.2 (± 0.2) |
-0.04 (± 0.2) |
1.8 (± 0.08) |
-0.2 (± 0.1) |
-0.2 (± 0.1) |
-0.2 (± 0.2) |
+0.3 (± 0.2) |
| **Total mornings |
4.1 (± 1.0) |
-0.07 (± 0.5) |
-0.2 (± 0.3) |
-0.8 (± 0.4) |
-0.2 (± 0.5) |
3.5 (± 0.7) |
-1.1 (± 0.5) |
-0.8 (± 0.6) |
-0.3 (± 0.7) |
+0.1 (± 0.5) |
| **Total awakenings |
3.7 (± 1.3) |
-1.1 (± 0.7) |
-0.3 (± 1.7) |
+0.7 (± 2.4) |
-0.2 (± 0.7) |
1.4 (± 0.5) |
-0.8 (± 0.4) |
-0.9 (± 0.5) |
+0.2 (± 0.7) |
+0.9 (± 0.8) |
|
|
||||||||||
|
Reid et al. Journal of Negative Results in BioMedicine 2008 7:3 doi:10.1186/1477-5751-7-3 |
||||||||||
